

Alyssa M Peckham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007597/publications.pdf>

Version: 2024-02-01

41
papers

765
citations

623734

14
h-index

552781

26
g-index

41
all docs

41
docs citations

41
times ranked

737
citing authors

#	ARTICLE	IF	CITATIONS
1	Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. <i>Drugs</i> , 2021, 81, 125-156.	10.9	94
2	Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 953-958.	3.0	70
3	Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. <i>Risk Management and Healthcare Policy</i> , 2018, Volume 11, 109-116.	2.5	69
4	All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population. <i>Drug Safety</i> , 2018, 41, 213-228.	3.2	58
5	Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race. <i>Journal of Attention Disorders</i> , 2020, 24, 10-19.	2.6	52
6	Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population. <i>Clinical Drug Investigation</i> , 2017, 37, 763-773.	2.2	42
7	Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. <i>Substance Abuse: Research and Treatment</i> , 2018, 12, 117822181880131.	0.9	42
8	Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population. <i>Pharmacotherapy</i> , 2018, 38, 436-443.	2.6	37
9	Prevalence and characteristics of self-reported kratom use in a representative US general population sample. <i>Journal of Addictive Diseases</i> , 2020, 38, 506-513.	1.3	33
10	Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. <i>CNS Spectrums</i> , 2019, 24, 287-312.	1.2	28
11	Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 613-618.	1.0	24
12	Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa503.	0.9	24
13	A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution Program. <i>Journal of Public Health Management and Practice</i> , 2018, 24, 310-317.	1.4	22
14	Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. <i>Journal of Substance Abuse Treatment</i> , 2021, 126, 108316.	2.8	19
15	Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1055-1064.	2.1	17
16	Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S89-S99.	2.0	15
17	Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?. <i>Mental Health Clinician</i> , 2018, 8, 175-183.	1.0	15
18	Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 519-523.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion. <i>Mental Health Clinician</i> , 2016, 6, 277-284.	1.0	11
20	Rapid Buprenorphine Microdosing for Opioid use Disorder in a Hospitalized Patient Receiving Very High Doses of Full Agonist Opioids for Acute Pain Management: Titration, Implementation Barriers, and Strategies to Overcomes. <i>Substance Abuse</i> , 2021, 42, 506-511.	2.3	10
21	State-level response to gabapentin misuse in the United States: Implications and future direction. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, e143-e148.	1.0	10
22	Evaluation of a peer- and self-grading process for clinical writing assignments. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 979-986.	1.0	6
23	VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications. <i>Journal of Pharmacy Practice</i> , 2019, 32, 450-457.	1.0	6
24	Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108416.	2.8	6
25	Call for increased pharmacovigilance of gabapentin. <i>BMJ: British Medical Journal</i> , 2017, 359, j5456.	2.3	5
26	Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. <i>Clinical Drug Investigation</i> , 2021, 41, 245-253.	2.2	5
27	Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women. <i>Obstetrics and Gynecology</i> , 2021, 137, 377-378.	2.4	5
28	Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. <i>Mental Health Clinician</i> , 2021, 11, 225-230.	1.0	5
29	Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?. <i>Drugs - Real World Outcomes</i> , 2018, 5, 69-79.	1.6	3
30	Need for international classification of gabapentin as a controlled substance. <i>BMJ: British Medical Journal</i> , 2018, 363, k4978.	2.3	3
31	High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance. <i>Preventive Medicine Reports</i> , 2019, 15, 100892.	1.8	3
32	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. <i>Journal of Substance Abuse Treatment</i> , 2020, 119, 108141.	2.8	3
33	Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update". <i>Drugs</i> , 2021, 81, 615-617.	10.9	3
34	Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration. <i>BMC Research Notes</i> , 2018, 11, 523.	1.4	1
35	Authors' Reply to: Tomoyuki Kawada's Comment on: "All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population". <i>Drug Safety</i> , 2018, 41, 643-644.	3.2	1
36	Combined Gabapentinoid and Opioid Use. <i>Annals of Internal Medicine</i> , 2019, 170, 908.	3.9	1

#	ARTICLE	IF	CITATIONS
37	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Substance Abuse: Research and Treatment, 2020, 14, 117822181989458.	0.9	1
38	Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth" Pain and Therapy, 2021, 10, 751-755.	3.2	1
39	Management of Opioid Agonist Treatment for Opioid use Disorder in the Setting of Solid Organ Transplant. Transplantation, 2021, Publish Ahead of Print, .	1.0	1
40	Quantifying Gabapentin Misuse With Opioids. primary care companion for CNS disorders, The, 2019, 21, .	0.6	1
41	Trichotillomania: Improved Clinical Outcomes with a Novel Psychotropic Combination-Treatment Regimen. Psychiatric Annals, 2019, 49, 135-136.	0.1	0